Alan Barnicle

658 total citations
19 papers, 212 citations indexed

About

Alan Barnicle is a scholar working on Oncology, Genetics and Reproductive Medicine. According to data from OpenAlex, Alan Barnicle has authored 19 papers receiving a total of 212 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Genetics and 10 papers in Reproductive Medicine. Recurrent topics in Alan Barnicle's work include PARP inhibition in cancer therapy (15 papers), BRCA gene mutations in cancer (10 papers) and Ovarian cancer diagnosis and treatment (9 papers). Alan Barnicle is often cited by papers focused on PARP inhibition in cancer therapy (15 papers), BRCA gene mutations in cancer (10 papers) and Ovarian cancer diagnosis and treatment (9 papers). Alan Barnicle collaborates with scholars based in United Kingdom, Canada and Spain. Alan Barnicle's co-authors include J. Carl Barrett, Elizabeth A. Harrington, John M. Greally, Aaron Golden, Carrie A. Adelman, Laurence J. Egan, Cathal Seoighe, Zhongwu Lai, Jinyu Kang and Antoine Thiery-Vuillemin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Alan Barnicle

17 papers receiving 210 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Barnicle United Kingdom	8	136	101	76	64	44	19	212
A. Allen United States	7	138 1.0×	87 0.9×	62 0.8×	32 0.5×	15 0.3×	11	164
Nicolas Dorvault France	7	119 0.9×	46 0.5×	161 2.1×	66 1.0×	10 0.2×	12	237
Imre Pete Hungary	10	78 0.6×	28 0.3×	110 1.4×	58 0.9×	89 2.0×	22	261
Kathleen Klein Oros Canada	6	63 0.5×	59 0.6×	111 1.5×	67 1.0×	32 0.7×	8	195
K.M. Bell-McGuinn United States	5	152 1.1×	20 0.2×	81 1.1×	36 0.6×	113 2.6×	10	219
Yannick Boursin France	6	69 0.5×	35 0.3×	75 1.0×	67 1.0×	75 1.7×	9	190
Hasan Mirza United Kingdom	8	97 0.7×	33 0.3×	93 1.2×	61 1.0×	31 0.7×	19	198
Simon P. Watkins United States	7	147 1.1×	65 0.6×	60 0.8×	16 0.3×	22 0.5×	17	166
Daniel C. Bruhm United States	8	71 0.5×	70 0.7×	113 1.5×	163 2.5×	29 0.7×	11	243
Eva María Guerra Alia Spain	7	127 0.9×	28 0.3×	46 0.6×	13 0.2×	118 2.7×	15	183

Countries citing papers authored by Alan Barnicle

Since Specialization

Citations

This map shows the geographic impact of Alan Barnicle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Barnicle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Barnicle more than expected).

Fields of papers citing papers by Alan Barnicle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Barnicle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Barnicle. The network helps show where Alan Barnicle may publish in the future.

Co-authorship network of co-authors of Alan Barnicle

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Barnicle. A scholar is included among the top collaborators of Alan Barnicle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Barnicle. Alan Barnicle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Pignata, Sandro, Amit M. Oza, Geoff Hall, et al.. (2025). Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status. British Journal of Cancer. 132(8). 725–732.

Liu, Ying L., Cara Mathews, Fiona Simpkins, et al.. (2025). Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis. Cancer. 131(2). e35707–e35707. 1 indexed citations

Poveda, Andrés, Stéphanie Lheureux, Nicoletta Colombo, et al.. (2025). Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial. Gynecologic Oncology. 197. 74–82.

Shore, Neal D., Noel W. Clarke, Andrew J. Armstrong, et al.. (2024). Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.. Journal of Clinical Oncology. 42(4_suppl). 165–165. 1 indexed citations

Lukashchuk, Natalia, Alan Barnicle, Carrie A. Adelman, et al.. (2023). Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Frontiers in Oncology. 13. 1162644–1162644. 16 indexed citations

Pignata, Sandro, Amit M. Oza, Geoff Hall, et al.. (2023). Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. Gynecologic Oncology. 172. 121–129. 12 indexed citations

N., Kim, Alan Barnicle, Zhongwu Lai, et al.. (2022). Detection of BRCA1 , BRCA2 , and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clinical Cancer Research. 29(1). 81–91. 46 indexed citations

Armstrong, Andrew J., Antoine Thiery-Vuillemin, Neal D. Shore, et al.. (2022). 1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. Annals of Oncology. 33. S1168–S1168. 6 indexed citations

Poveda, Andrés, Stéphanie Lheureux, Nicoletta Colombo, et al.. (2022). Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecologic Oncology. 164(3). 498–504. 29 indexed citations

10.

Lheureux, Stéphanie, Ana Oaknin, Magdalena Sikorska, et al.. (2022). Clinical and molecular characteristics of patients with short- and long-term progression-free survival in the phase IIIb OPINION study of maintenance olaparib for patients with non-germline BRCA1/BRCA2-mutated platinum-sensitive relapsed ovarian cancer (306). Gynecologic Oncology. 166. S160–S160. 1 indexed citations

11.

Pignata, Sandro, Amit M. Oza, Geoff Hall, et al.. (2022). Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.. Journal of Clinical Oncology. 40(16_suppl). 5519–5519. 4 indexed citations

12.

Pignata, Sandro, Amit M. Oza, Geoff Hall, et al.. (2021). ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status. Gynecologic Oncology. 162. S29–S29. 4 indexed citations

13.

N., Kim, Alan Barnicle, Zhongwu Lai, et al.. (2021). Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study.. Journal of Clinical Oncology. 39(6_suppl). 26–26. 22 indexed citations

14.

Lindemann, Kristina, Erik Škof, Nicoletta Colombo, et al.. (2021). 740P Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study. Annals of Oncology. 32. S738–S739. 2 indexed citations

15.

Carr, T. Hedley, Carrie A. Adelman, Alan Barnicle, et al.. (2021). Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers. 13(22). 5830–5830. 20 indexed citations

16.

Poveda, Andrés, Stéphanie Lheureux, Nicoletta Colombo, et al.. (2020). Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.. Journal of Clinical Oncology. 38(15_suppl). 6057–6057. 7 indexed citations

17.

Carr, T. Hedley, Carrie A. Adelman, Alan Barnicle, et al.. (2018). Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC). Annals of Oncology. 29. viii30–viii30. 1 indexed citations

18.

Barnicle, Alan, Cathal Seoighe, John M. Greally, Aaron Golden, & Laurence J. Egan. (2017). Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis. Epigenetics. 12(8). 591–606. 34 indexed citations

19.

Barnicle, Alan, Cathal Seoighe, Aaron Golden, John M. Greally, & Laurence J. Egan. (2016). Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells. Physiological Genomics. 48(4). 257–273. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact